Brave Asset Management Inc. Has $927,000 Stock Holdings in Pfizer Inc. (NYSE:PFE)

Brave Asset Management Inc. trimmed its holdings in shares of Pfizer Inc. (NYSE:PFE) by 15.4% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 32,195 shares of the biopharmaceutical company’s stock after selling 5,870 shares during the period. Brave Asset Management Inc.’s holdings in Pfizer were worth $927,000 at the end of the most recent quarter.

A number of other large investors also recently modified their holdings of PFE. Worth Asset Management LLC acquired a new position in shares of Pfizer during the 1st quarter worth about $29,000. Briaud Financial Planning Inc acquired a new stake in Pfizer in the 3rd quarter valued at about $30,000. GoalVest Advisory LLC lifted its stake in Pfizer by 304.9% in the 4th quarter. GoalVest Advisory LLC now owns 1,077 shares of the biopharmaceutical company’s stock valued at $31,000 after purchasing an additional 811 shares during the last quarter. Mizuho Securities Co. Ltd. acquired a new stake in Pfizer in the 3rd quarter valued at about $34,000. Finally, VisionPoint Advisory Group LLC lifted its stake in Pfizer by 52,350.0% in the 3rd quarter. VisionPoint Advisory Group LLC now owns 1,049 shares of the biopharmaceutical company’s stock valued at $35,000 after purchasing an additional 1,047 shares during the last quarter. 68.36% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several equities research analysts recently issued reports on the stock. Truist Financial cut their target price on shares of Pfizer from $42.00 to $36.00 and set a “buy” rating for the company in a research note on Thursday, December 14th. TD Cowen downgraded shares of Pfizer from an “outperform” rating to a “market perform” rating and set a $32.00 price objective for the company. in a research report on Thursday, January 4th. Guggenheim initiated coverage on shares of Pfizer in a report on Friday, February 23rd. They set a “buy” rating and a $36.00 target price on the stock. UBS Group decreased their price objective on shares of Pfizer from $34.00 to $27.00 and set a “neutral” rating on the stock in a research note on Thursday, December 14th. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating and set a $45.00 target price on shares of Pfizer in a research note on Friday, March 1st. Twelve equities research analysts have rated the stock with a hold rating and six have assigned a buy rating to the stock. Based on data from MarketBeat.com, Pfizer presently has a consensus rating of “Hold” and a consensus target price of $36.88.

Pfizer Stock Down 0.1 %

Shares of NYSE:PFE traded down $0.03 during midday trading on Thursday, hitting $27.75. 39,620,254 shares of the company’s stock were exchanged, compared to its average volume of 43,835,094. The company has a debt-to-equity ratio of 0.69, a current ratio of 0.91 and a quick ratio of 0.69. The stock has a 50 day moving average price of $27.46 and a 200-day moving average price of $29.46. The company has a market cap of $157.14 billion, a PE ratio of 77.08, a price-to-earnings-growth ratio of 1.24 and a beta of 0.61. Pfizer Inc. has a 12 month low of $25.61 and a 12 month high of $42.22.

Pfizer (NYSE:PFE) last issued its quarterly earnings data on Tuesday, January 30th. The biopharmaceutical company reported $0.10 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.19) by $0.29. Pfizer had a net margin of 3.62% and a return on equity of 10.88%. The business had revenue of $14.25 billion during the quarter, compared to the consensus estimate of $14.37 billion. During the same period in the prior year, the firm posted $1.14 EPS. The firm’s quarterly revenue was down 41.3% compared to the same quarter last year. On average, sell-side analysts anticipate that Pfizer Inc. will post 2.22 EPS for the current fiscal year.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.